Do you consider neoadjuvant pertuzumab for node negative multifocal HER2+/ER+ IDC without any single focus >2 cm?   

A patient with multifocal disease is at increased risk of distant recurrence compared to a patient with a single focus of disease that is the same size as the first patient's largest focus, even though they are considered to have the same disease stage, a shortcoming of our staging system which shou...

When thinking of multifocal disease, by definition it is biologically and clinically high risk. You have to think in terms of Field cancerization. It is best to consider it.